Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22073588 | 0.89 | CYP3A4 (0.67) | CYP3A4PTGESMT-CO2MEN1KMT2A | |
| SCHEMBL22077263 | 0.89 | CYP3A4 (1.00) | CYP3A4PTGESMT-CO2MEN1KMT2A | |
| SCHEMBL22073636 | 0.85 | CYP3A4 (0.68) | CYP3A4PTGESMEN1KMT2ATRPV1 | |
| SCHEMBL31087517 | 0.85 | CYP3A4 (0.68) | CYP3A4PTGESMEN1KMT2ATRPV1 | |
| SCHEMBL22076803 | 0.85 | CYP3A4 (0.68) | CYP3A4PTGESMEN1KMT2ATRPV1 | |
| SCHEMBL22073635 | 0.85 | CYP3A4 (0.70) | CYP3A4PTGESMT-CO2MEN1KMT2A | |
| SCHEMBL6868015 | 0.83 | PTGES (0.68) | CYP3A4PTGESMEN1KMT2ATRPV1 | |
| SCHEMBL22027542 | 0.82 | CYP3A4 (0.63) | CYP3A4PTGESMEN1KMT2ALMNA | |
| SCHEMBL22073631 | 0.82 | CYP3A4 (0.63) | CYP3A4PTGESMEN1KMT2ALMNA | |
| SCHEMBL31087523 | 0.82 | CYP3A4 (0.63) | CYP3A4PTGESMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680219-A2 | ACETAMINOPHEN COMPOSITIONS AND METHODS OF TREATING CANCER | The United States Government as represented by the Department of Veterans Affairs (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2024192214-A2 | ACETAMINOPHEN COMPOSITIONS AND METHODS OF TREATING CANCER | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-3672938-B1 | COMPOUNDS FOR AMELIORATING PAIN | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20200179393-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING PAIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179393-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING PAIN | ACHE, MPO, MMP8 | CYP3A4 4236/4885PTGES 38/4885MT-CO2 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.